Veru Inc. VERU
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Veru Inc. (VERU) is a healthcare company listed in the US with a market value of about $36M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -109%.
About Veru
Veru is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $14M in 2017 to $17M in 2024, growth of about 3.1% a year. It was profitable in 1 of the last 9 years in our data. Its share count rose by 83% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $17M | $16M | $39M | $61M | $43M | $32M | $16M | $14M |
| Net income | -$23M | -$38M | -$93M | -$84M | $7M | -$19M | -$12M | -$24M | -$7M |
| Free cash flow | -$30M | -$22M | -$89M | -$48M | -$16M | -$2M | -$6M | -$12M | $849402 |
| EPS (diluted) | $-1.55 | $-2.80 | $-11.00 | $-10.50 | $0.90 | $-2.80 | $-1.90 | $-4.40 | $-2.50 |
| Net margin | — | -223.9% | -571.6% | -213.5% | 12.1% | -44.5% | -37.8% | -150.9% | -48.4% |
| ROIC | -91.2% | -78.7% | -304.3% | -75.1% | 6.6% | -37.2% | -15.5% | -43.5% | -13.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Veru pay a dividend?
Not currently.
Is Veru a good stock to buy?
We do not give buy or sell advice. Veru scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.